论文部分内容阅读
Somatostatin受体阳性肿瘤显像剂111In－DTPA－D－Phe1－octreotide在体内降解产物为111In－DTPA，给药后3h血中111In－DTPA占血中放射性的50％，尿中为40％。正常鼠与载胰腺癌裸鼠的动物实验表明：该显像剂的血液清除很快，注射后10min血液的％ID／g为注射后1min的50％；放射性主要从泌尿系统排泄，给药后4min膀胱显影，至30min双肾和膀胱的放射性含量达50％ID；T／B比值在给药后逐渐增高，至24h可达7．92；给药后0．5－24h均可进行载胰腺癌裸鼠模型上的肿瘤阳性显像，24h时相的图像质量最佳。
The in vivo degradation product 111In-DTPA-D-Phe1-octreotide of Somatostatin receptor-positive tumor imaging agent was 111In-DTPA. In the blood at 3h after administration, 111In-DTPA accounted for 50% of radioactivity in blood and 40% in urine. Experiments in normal mice and nude mice bearing pancreatic cancer showed that the blood clearance of the imaging agent was rapid, and the % ID/g of blood at 10 min after injection was 50% of that at 1 min after injection; radioactivity was mainly excreted from the urinary system and after administration After 4 minutes of bladder imaging, the radioactivity of both kidneys and bladder reached 50% ID by 30 minutes; the ratio of T/B was gradually increased after administration, reaching 7.92 at 24 hours; and the pancreas could be carried at 0.5-24 hours after administration. Tumor-positive imaging was performed on nude mice and the image quality was best at 24 hours.